New insights into change of lens proteins' stability with ageing under physiological conditions. Issue 3 (30th September 2021)

• Record Type: Journal Article
• Authors: Luo, Chenqi; Xu, Jingjie; Fu, Chenxi; Yao, Ke; Chen, Xiangjun
• Is Part Of: British journal of ophthalmology. Volume 107:Issue 3(2023)
• Page Start: 442
• Page End: 446
• Publication Date: 2021-09-30
• Subjects: lens and zonules -- experimental – animal models; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2021-319834
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Background: Age-related cataract, which presents as a cloudy lens, is the primary cause of vision impairment worldwide and can cause more than 80% senile blindness. Previous studies mainly explored the profile of lens proteins at a low concentration because of technical limitations, which could not reflect physiological status. This study focuses on protein stability changes with ageing under physiological conditions using a novel equipment, Unchained Labs (Uncle), to evaluate protein thermal stability. Methods: Samples were assessed through Unchained Labs, size-exclusion chromatography, western blot and biophysics approaches including the Thioflavin T, ultraviolet and internal fluorescence. Results: With age, the melting temperature value shifted from 67.8°C in the young group to 64.2°C in the aged group. Meanwhile, crystallin may form more isomeric oligomers and easy to be degraded in aged lenses. The spectroscopic and size-exclusion chromatography results show a higher solubility after administrated with lanosterol under the environmental stress. Conclusion: We are the first to explore rabbit lens protein stability changes with ageing using biophysical methods under physiological conditions, and this study can conclude that the structural stability and solubility of lens proteins decrease with ageing. Additionally, lanosterol could aid in resolving protein aggregation, making it a potential therapeutic option for cataracts. So, this study provides cataract models for anti-cataract drug developments